Setting a Standard in RSV Protection | October 15 | 5:00 PM | Free Registration
Speaker: Stuart Cohen, MD
Agenda:
Welcome & introductions
Presentation: Setting a standard in RSV protection
- Beyfortus key topics: RSV disease burden, setting a standard, pivotal trials, real-world evidence, and considerations for implementation
Audience discussion
Please RSVP by 10/12/2026 via email to Carrie Vosburg at carrie.vosburg@sanofi.com
Indication:
Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:
- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
IMPORTANT SAFETY INFORMATION
Contraindication
Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.
Warnings and Precautions
- Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
- Use in Individuals with Clinically Significant Bleeding Disorders: As with any other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder, or to individuals on anticoagulation therapy.
- Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).
Please see accompanying full Prescribing Information.
